Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 7686 results

  1. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

    Awaiting development [GID-TA11231] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]

    In development [GID-TA10999] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Falls: assessment and prevention in older people and people 50 and over at higher risk (update)

    In development [GID-NG10228] Expected publication date: 26 March 2025

    NICE guideline
    In development

  4. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  5. Falls: assessment and prevention in older people and people 50 and over at higher risk (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 28 November 2024.

    NICE guideline
    In consultation

  6. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 20 November 2024.

    Technology appraisal guidance
    In consultation

  7. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (DG60)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD)

    Diagnostics guidance
    Published
    21 October 2024
    View recommendations

    Sections for DG60

  8. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (DG61)

    Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices

    Diagnostics guidance
    Published
    24 October 2024
    View recommendations

    Sections for DG61

  9. Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211

    In development [GID-TA11201] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  10. Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway

    In development [GID-HTE10047] Expected publication date: 19 December 2024

    Health technology evaluations
    In development

  11. Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491

    Awaiting development [GID-TA11075] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Ublituximab for treating relapsing multiple sclerosis [ID6350]

    In development [GID-TA11268] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tirzepatide for managing overweight and obesity [ID6179]

    In development [GID-TA11156] Expected publication date: 19 December 2024

    Technology appraisal guidance
    In development

  14. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development [GID-TA11343] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

    In development [GID-TA11570] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development